Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Lancet 390(10110):23472359
Pan R, Ruvolo PP, Pellecchia M, Wei J, Shi Y, Konopleva M, Reed JC, Andreeff M
Type 2 diabetes increasingly represents a risk factor associated not only to cardiometabolic pathologies but also to neurological conditions
Given the wide popularity of GLP-1 drugs, the public now increasingly recognizes that using medication to treat obesity is as legitimate as using insulin for diabetes or a statin for high cholesterol
Health Canada has approved six medications specifically for chronic weight management: orlistat (Xenical), liraglutide (Saxenda), naltrexone-bupropion (Contrave), semaglutide (Wegovy), tirzepatide (Zepbound), and setmelanotide (Imcivree, for rare genetic forms of obesity only)
US$ 25.30
US$ 25.34
:max_bytes(150000):strip_icc()/insulin-injection-478185779-594b3cae3df78cae8111498f.jpg)
US$ 24.83
US$ 20.60
:max_bytes(150000):strip_icc()/GettyImages-601234926-5afb277e6bf0690036144c14.jpg)
